USANA (NYSE:USNA) Misses Q2 CY2026 Sales Expectations, Stock Drops 19.2%
USANA Health Sciences (NYSE:USNA) reported Q2 CY2026 sales of $223 million, down 5.4% year on year, missing market expectations and sending the stock down 19.2% to $18.41. The company said full-year revenue guidance is $962.5 million at the midpoint, 1.8% above analysts’ estimates. Non-GAAP EPS was a $0.07 loss, better than consensus.
How this was made
The 30-second read
Why it matters
Traders likely focus on the quarterly revenue miss and EPS shortfall as the primary driver of the sharp selloff, while the full-year revenue guidance beat and non-GAAP loss beat provide partial support.
Market read
A clear earnings-style datapoint with both a downside (Q2 revenue and EPS misses) and an offset (full-year revenue guidance beat, non-GAAP loss beat) that can drive positioning into the next earnings cycle.
What to watch
The article notes non-GAAP loss of $0.07 per share beat consensus and EBITDA expectations were exceeded, which could soften the revenue-miss narrative if follow-through appears in subsequent quarters.
Background
USANA sells nutritional and skincare products via a direct selling model and reported Q2 CY2026 results with a revenue decline versus the prior year.
Ticker impact
USANA reported Q2 CY2026 revenue of $223M, down 5.4% YoY, missing expectations, and shares fell 19.2% after the print.
Bearish near-term bias, with potential stabilization only if investors focus on the full-year revenue guidance beat.
The article provides a concrete earnings-style datapoint (Q2 revenue miss, EPS miss) plus a partial offset (full-year revenue guidance above consensus). The magnitude of the immediate drop (19.2%) suggests the market is prioritizing the miss.
Market effects
Signals continued demand pressure for direct-selling health and wellness brands, even when full-year revenue guidance holds up.
No specific regional spillover described beyond US small consumer staples sentiment.
No global macro or international demand drivers cited.
Counterpoint
Investors may re-rate the stock if the full-year revenue guidance beat (midpoint $962.5M) indicates the Q2 weakness is temporary and margins/cash flow improve.
Key entities
- companyUSANA Health Sciences
Reported Q2 CY2026 revenue of $223M (down 5.4% YoY), missed expectations, and guided full-year revenue to $962.5M at the midpoint.
